1 / 15

NAACCR/IACR Combined Annual Conference 6/11/2019, Vancouver, Canada

Primary Malignant Cardiac Tumors in California Lihua Liu, PhD Los Angeles Cancer Surveillance Program University of Southern California. NAACCR/IACR Combined Annual Conference 6/11/2019, Vancouver, Canada. Primary Malignant Cardiac Tumor (PMCT ). Cancer occurring in the heart

booth
Télécharger la présentation

NAACCR/IACR Combined Annual Conference 6/11/2019, Vancouver, Canada

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Primary Malignant Cardiac Tumors in CaliforniaLihua Liu, PhDLos Angeles Cancer Surveillance ProgramUniversity of Southern California NAACCR/IACR Combined Annual Conference 6/11/2019, Vancouver, Canada

  2. Primary Malignant Cardiac Tumor (PMCT) • Cancer occurring in the heart • Rare (AAIR=0.034/100,0001) • Highly fatal (Median survival=10 months1) • Most are diagnosed at late stage • Under-researched • Poorly understood 1. Oliveira GH, Al-Kindi SG, ChristopherDOH, Park SJ. Characteristics and Survival of Malignant Cardiac Tumors A 40-Year Analysis of >500 Patients. Circulation, December 2015: 2395-2402.

  3. Methods • California Cancer Registry (CCR) data (1988-2016) • SEER site recode (soft tissue incl. heart) & ICD-O-3 (heart) • N = 247 • PMCT disparities by patient and tumor characteristics • Case distributions • Incidence rates (age-adjusted, age-specific) • Survival (Kaplan–Meier estimates, Cox regression analysis)

  4. PMCT Case Distribution by Race/ethnicity,California, 1988-2016 (N=247)

  5. PMCT Age-Adjusted Incidence Rates (AAIR) by Race/ethnicityCalifornia, 1988-2016

  6. PMCT Case Distribution by Age Group,California, 1988-2016 (N=247)

  7. PMCT Age-Specific Incidence Rates (ASIR) by Race/ethnicityCalifornia, 1988-2016

  8. Trends of PMCT AAIR by Sex, California, 1988-2016

  9. PMCT Case Distribution by Tumor Stage at Diagnosis,California, 1988-2016 (N=247)

  10. PMCT Observed Survival by Tumor Stage,California, 1988-2016

  11. PMCT Case Distribution by Treatment Type,California, 1988-2016 (N=247)

  12. PMCT Observed Survival by Treatment Type,California, 1988-2016

  13. Multivariate analysis – Hazard Ratios

  14. Summary • PMCT incidence rates are similar between males and females, but higher in NH blacks and Hispanics (not statistically significant, maybe due to small numbers) • Risk of PMCT increases with age, AAIR trends rising slightly • Only 27% of PMCT patients were diagnosed at localized stage • Observed 3-year survival is below 20% • Early stage diagnosis and combination of treatment modalities lead to the best outcomes • Mining cancer registry data can provide valuable information for understanding PMCT and improving diagnosis and survival

  15. Acknowledgments • University of Southern California • Megan Loo, MD, MPH, Cardiothoracic Surgery Resident • Juanjuan Zhang, MS, Dept. of Preventive Medicine • Sue E. Kim, PhD, Dept. of Preventive Medicine • Michael Bowdish, MD, MS, Depts. of Surgery and Preventive Medicine • The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under cooperative agreement 5NU58DP006344; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors.

More Related